DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of claims 1-6 in the reply filed on 22 September 2026 is acknowledged. Claims 7-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Claim Objections
Claim 3 is objected to because of the following informalities: write out MCT the first time it is used in the claims. Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 6 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 6 recites “traditional teas.” The specification does not provide a definition for traditional teas. It is unclear what properties a tea must have in order to be considered traditional. For the purpose of examination, 6 will be interpreted as any composition comprising tea leave is considered traditional.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1 and 6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kim (KR20090062615A). All citations to Kim refer to the English translation.
Regarding claim 1, Kim discloses a powder tea and the method for producing the same [2]. Kim discloses pulverizing roasted soybeans and mixing with peanut (both of which comprise lipids), corn starch and roasted rice bran (organic materials) and powdered fat and filling the tea bags with the mixed powder (Beginning of [4]). Kim’s mixed powder meets the claim limitation of a steepable organically based substance.
As to the claim language “wherein said organic material and lipid are mixed together, heated and agitated while heating to produce a base material, wherein said base material is cooled, wherein said base material is then ground to a desired size to produce a ground base material, and wherein said ground base material is then mixed with a powdered lipid to produce said steepable organic substance,” this is product by process claim language. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. MPEP 2113 I. Additionally, where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. MPEP 2112.01 I. Since Kim discloses the organic material, lipid and powdered fat are mixed as a powder to be used as tea, the product of the prior art is materially indistinguishable from the composition produced by the recited product by process claim limitations.
Regarding claim 6, Kim discloses the powder tea comprises salt, pine nuts and walnut (flavors) [4].
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-6 are rejected under 35 U.S.C. 103 as being unpatentable over Reillo (US 2016/0310443 A1) in view of Orgain (MCT oil vs MCT Powder: What makes them different (2021) https://orgain.com/blogs/blogs/mct-oil-vs-mct-powder?srsltid=AYCX9vLcbuN9cRMsa7freuv1gnNFrQ7Pe_4TN6lUD4lE7wd3LI85DvTU) and Feel State (The complete guide to cannabis oil infusions, 2021 https://feelstate.com/the-complete-guide-to-cannabis-oil-infusions/).
Regarding claims 1, 2, 4 and 5; Reillo discloses a lipophilic active agent infused food product comprising a lipophilic active agent, a bioavailability enhancing agent, and a food product [0010]. Reillo discloses the lipophilic active agent may be cannabinoid, the bioavailability enhancing agent may be an edible fat or oil, and the food product may be tea leaves [0010] [0036]. Reillo discloses an embodiment which comprises tea leaves, hemp oil and cannabis leaves [0069], which meet the claim limitation of a steepable organically based substance comprising organic material and a lipid.
Reillo does not disclose mixing in a powdered lipid.
Orgain, in the field of medium chain triglycerides (MCT’s), discloses MCT’s have multiple health benefits including decreasing insulin resistance and lowering body weight (p3). Orgain discloses MCT powder has a creamy texture when added to liquids and is best suited to beverages like coffee or tea (p2, Texture).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the cannabis, tea leaves and hemp oil of Reillo with the powdered MCT of Orgain since Orgain discloses the powdered MCT’s provide health benefits and are advantageously used in beverages like tea.
Reillo does not disclose the heating and grinding of the material
Feel State, in the field of cannabis oil infusions, discloses using coconut oil or MCT fractionated coconut oil for the infusion (p7). Feel state discloses grinding the material to increase the surface area of the plant material to allow for more effective infusion (p9, para 3). Feel State discloses heating your plant material in order to convert the THCA (Tetrahydrocannabinolic acid) to THC (tetrahydrocannabinol) and the CBDA (cannabidiolic acid) to CBD (Cannabidiol) via decarboxylation converts them to cannabinoids that bind well to human endocannabinoid receptors (p9, Step 3).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combined the cannabis leaves and oil of Reillo with the grinding and heating of Feel State in order to increase the surface area of the plant material with respect to the oil to allow a more effective infusion and also with the heating of Feel State in order to decarboxylate the THCA and CBDA into THC and CBD which bind well to the human endocannabinoid receptors.
As to the claim language “wherein said organic material and lipid are mixed together, heated and agitated while heating to produce a base material, wherein said base material is cooled, wherein said base material is then ground to a desired size to produce a ground base material, and wherein said ground base material is then mixed with a powdered lipid to produce said steepable organic substance,” this is product by process claim language. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. MPEP 2113 I. Additionally, where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. MPEP 2112.01 I. The product of the prior art is materially indistinguishable from the composition produced by the recited product by process claim limitations.
Regarding claim 3, Reillo discloses the oil may be glycerol triesters of medium chain fatty acids (medium chain triglycerides) [0037].
Regarding claim 6, Reillo discloses the food product may also comprise tea leaves, herbs, spices and/or flavoring agents [0010].
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-4 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 21 and 22 of copending Application No. 18/534,272 (reference application herein referred to as ‘272). Although the claims at issue are not identical, they are not patentably distinct from each other because:
Regarding claims 1-4, claims 21 and 22 of ‘272 disclose a cannabis plant material (organic material) a medium chain triglyceride oil (lipid) and a medium chain triglyceride oil powder (lipid powder). The edible organically based substance of ‘272 meets the claim limitation of a steepable organically based substance, since it can be soaked in liquid to achieve a concentration of organic material in the liquid.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. It is noted that claims 21 and 22 of Application No. 18/534,272 have been allowed, however the fees have not been paid and a patent number has not been issued. When the fees have been paid and the patent number issued, this rejection would become non-provisional.
Claims 5-6 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 21 and 22 of copending Application No. 18/534,272 in view of Reillo (US 2016/0310443 A1).
Regarding claims 5-6, as discussed above, claims 21 and 22 of ‘272 disclose the limitations of instant claim 1. ‘272 does not disclose the substance comprises tea.
Reillo, in the field of food products comprising cannabis, discloses a lipophilic active agent infused food product comprising a lipophilic active agent, a bioavailability enhancing agent, and a food product [0010]. Reillo discloses the lipophilic active agent may be cannabinoid, the bioavailability enhancing agent may be an edible fat or oil, and the food product may be tea leaves [0010] [0036]. Reillo discloses an embodiment which comprises tea leaves, hemp oil and cannabis leaves [0069].
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the composition of ‘272 claims 21 and 22 with the tea of Reillo since they are both drawn to edible mixtures of cannabis and lipids.
This is a provisional nonstatutory double patenting rejection. It is noted that claims 21 and 22 of Application No. 18/534,272 have been allowed, however the fees have not been paid and a patent number has not been issued. When the fees have been paid and the patent number issued, this rejection would become non-provisional.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARRIE GLIMM whose telephone number is (571)272-2839. The examiner can normally be reached Monday-Thursday 10:30-6:30 ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at 571-272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CARRIE GLIMM/Examiner, Art Unit 1793